IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2uPPrFj
via IFTTT